Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad.
The Mumbai-based drug maker said it has acquired Ondero and Ondero Met, including the trademark rights associated with these brands. The company said it has acquired two diabetes brands from Boehringer Ingelheim for an undisclosed amount.
Lupin has been marketing the two brands since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelheim India.
In India, an estimated 77 million people above the age of 18 years have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future. Ondero (Linagliptin) and Ondero Met (Linagliptin + Metformin) are the gold standard in diabetes management, Lupin stated.
Lupin Managing Director Nilesh Gupta said in a statement. Lupin MD Nilesh Gupta stated the action will further push them toward further consolidation of portfolio and strengthen their market leadership position in the antidiabetic segment by offering a wider spectrum of products and superior treatment.
Lupin India Regional Formulations President added to it, stating the acquisition represents their steadfast commitment to improve lives that are affected by the burden of a disease like diabetes and help patients navigate through the challenges that come with it.
